Intraoperative Kit for AuNP-Tissue Grafts

项目总结/摘要 所提出的技术是一种术中套件，由一种液体溶液组成， 纳米颗粒（AuNPs）在几分钟内转移到组织移植物。组织移植物，如ACL重建中使用的组织移植物 外科手术很少能达到100%移植物吸收，从而导致一系列问题。一个潜在的解决方案是 修饰移植物以增强整合并减少炎症，从而改善临床 结果。这项技术的创新是开发了术中试剂盒，以将AuNP附着到 在手术室里移植这些移植物可以是自体移植物或市售同种异体移植物、异种移植物， 或任何其它天然材料，例如胶原蛋白或3D打印组织。该项目的具体目标将 验证术中AuNP-组织缀合方法的概念。两个具体目标将严格 追求，其中包括1）通过生产AuNP移植物来优化术中试剂盒方法， 炎症，同时通过体外研究增加细胞增殖，和2）验证炎症 在ACL重建体内模型中修饰的移植物的调节能力和细胞增殖。 目前，还没有商业化的技术来修饰生物移植物以促进重塑和 减少炎症。本研究的意义在于开发一种术中方法来修改 生物移植物，以改善临床表现。主要研究者和分包主要研究者有专业知识， 该STTR第1阶段提案的目标;他们拥有多年的开发纳米材料组织的经验 生物纳米复合材料，并已参与了几个初创公司。

Project Summary/Abstract The proposed technology is an intraoperative kit comprised of a liquid solution which will conjugate gold nanoparticles (AuNPs) to tissue grafts within minutes. Tissue grafts, such as those used in ACL reconstruction surgery, rarely achieve 100% graft assimilation, thereby leading to a host of problems. A potential solution is to modify the grafts in order to enhance integration and reduce inflammation and thus improve clinical outcomes. The innovation of this technology is the development of the intraoperative kit to attach AuNPs to grafts in surgical suite settings. These grafts can be autografts or commercially available allografts, xenografts, or any other natural materials such as collagen or 3D printed tissues. The specific aims of the project will validate the concept of an intraoperative AuNP-tissue conjugation method. Two specific aims will be rigorously pursued, which include 1) optimizing the intraoperative kit method by producing AuNP grafts that reduce inflammation while increasing cellular proliferation via in vitro studies and 2) validating the inflammation modulation ability and cellular proliferation of the modified grafts in an ACL reconstruction in vivo model. Currently, there are no commercial technologies that modify biologic grafts in order to promote remodeling and reduce inflammation. The significance of this research is the development of an intraoperative method to modify biological grafts to improve clinical performance. The PI and sub-contract PI have the expertise to pursue the aims of this STTR Phase 1 proposal; they have years of experience developing nanomaterial-tissue bionanocomposites and have been involved with several start-up companies.